---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-034819"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:43:57.971850+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ImmuCell Q3 product sales $5.5M (-8% YoY); net loss narrows to $140k; gross margin recovers to 43%

## Summary
- Product sales Q3 2025: $5.5M, down 8% YoY; nine-month 2025: $20.0M, up 7% YoY.
- Net loss Q3 2025: ($140k) or ($0.02)/share vs ($702k) loss in Q3 2024.
- Net income nine-month 2025: $1.8M ($0.20 diluted) vs ($2.7M) loss in prior period.
- Gross margin improved to 43% Q3 2025 vs 26% Q3 2024; nine-month 42.6% vs 27.3%.
- Adjusted EBITDA Q3: $751k vs $196k; nine-month: $4.4M vs $35k; cash $3.9M, no debt drawn.

## SEC filing metadata
- accession: 0001437749-25-034819
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000143774925034819/0001437749-25-034819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000143774925034819/iccc20251113_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-034819
- JSON: https://secwatch.observer/filing/0001437749-25-034819.json
- Plain text: https://secwatch.observer/filing/0001437749-25-034819.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.